Cancer risk prediction models: a workshop on development, evaluation, and application.
暂无分享,去创建一个
Andrew N Freedman | Mitchell H Gail | Graham A Colditz | Ruth M Pfeiffer | G. Colditz | P. Hartge | D. Seminara | M. Gail | R. Pfeiffer | A. Freedman | Daniela Seminara | Patricia Hartge | Rachel Ballard-Barbash | R. Ballard-Barbash
[1] D. Easton,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.
[2] N. Risch,et al. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer , 1993, Breast Cancer Research and Treatment.
[3] W. Willett,et al. Harvard Report on Cancer Prevention Volume 4: Harvard Cancer Risk Index , 2004, Cancer Causes & Control.
[4] David F Ransohoff,et al. Using Risk for Advanced Proximal Colonic Neoplasia To Tailor Endoscopic Screening for Colorectal Cancer , 2003, Annals of Internal Medicine.
[5] W. E. Hoogendoorn,et al. Modeling familial clustered breast cancer using published data. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[6] S. Fisher,et al. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) , 2003, Breast Cancer Research.
[7] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[8] Sowmya R. Rao,et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.
[9] J. Hopper,et al. A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history. , 2003, Breast.
[10] P. Pharoah,et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.
[11] C. Begg,et al. Variations in lung cancer risk among smokers. , 2003, Journal of the National Cancer Institute.
[12] A. Oshima,et al. Estimation of individualized probabilities of developing breast cancer for Japanese women , 2003, Breast cancer.
[13] S. Selvachandran,et al. Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: a prospective study , 2002, The Lancet.
[14] Giovanni Parmigiani,et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Swindle,et al. Nomograms and instruments for the initial prostate evaluation: the ability to estimate the likelihood of identifying prostate cancer. , 2002, Seminars in urologic oncology.
[16] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Benítez,et al. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing , 2002, International journal of cancer.
[18] N E Day,et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.
[19] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[20] H. Nevanlinna,et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.
[21] G. Colditz,et al. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.
[22] N. Carson,et al. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center , 2000, Clinical genetics.
[23] M H Gail,et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.
[24] M. Kattan,et al. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. , 1999, Urology.
[25] E Graf,et al. Assessment and comparison of prognostic classification schemes for survival data. , 1999, Statistics in medicine.
[26] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[27] S. Seal,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[28] S Wacholder,et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. , 1999, American journal of human genetics.
[29] M. Diefenbach,et al. Prostate Cancer Risk Assessment Program , 1999 .
[30] M. Diefenbach,et al. Prostate cancer risk assessment program. A model for the early detection of prostate cancer. , 1999, Oncology.
[31] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[32] A. Zwinderman,et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. , 1998, The New England journal of medicine.
[33] S. Cummings,et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S M Grundy,et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. , 1998, Circulation.
[35] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[36] I. Thompson,et al. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. , 1997, Urology.
[37] K Offit,et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.
[38] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[39] G A Colditz,et al. Nurses' health study: log-incidence mathematical model of breast cancer incidence. , 1996, Journal of the National Cancer Institute.
[40] A. Whittemore,et al. Rates and Risks of Ovarian Cancer in Subgroups of White Women in the United States , 1994, Obstetrics and gynecology.
[41] N. Risch,et al. Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .
[42] R. Thompson,et al. Revisions in the risk‐based breast cancer screening program at group health cooperative , 1990, Cancer.
[43] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[44] M. Badzioch,et al. RISK OF FAMILIAL BREAST CANCER , 1984, The Lancet.
[45] M. King,et al. PRACTICAL GUIDE FOR ESTIMATING RISK FOR FAMILIAL BREAST CANCER , 1983, The Lancet.
[46] W. Kannel,et al. A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.